Clinical Trial ID:
A Clinical Trial to Gather Prospective and Retrospective Data on the Recurrence Rates for Female Breast Patients Receiving Radiation Therapy at Baptist MD Anderson Cancer Center
The primary aim of this study is to collect data prospectively and retrospectively, on the breast cancer recurrence rates on female patients who have received radiation treatment for their diagnosis of breast cancer. Data collected will provide future knowledge and analysis of specific local BMDA results of radiation treatment in the primary treatment of breast cancer patients. This data is generally reported and tracked at other major cancer centers and is important for BMDA to initiate a process for gathering the breast cancer recurrence rates and to be knowledgeable of our patient outcomes that can provide significant data for publications and education. BMDA treatment outcomes can be compared with other institutions’ published data with a potential opportunity to identify similar community and regional trends and collaborate on publication opportunities.
The primary aim of this study is to collect data prospectively and retrospectively, on the breast cancer recurrence rates on female patients who have received radiation treatment for their diagnosis of breast cancer.
After approval from the Institutional Review Board (IRB) and upon the initiation of this Registry study, new patients diagnosed with breast cancer and scheduled for Radiation Therapy (RT) will be identified and entered into the Registry database. Patients who were diagnosed and treated beginning in October through the initiation date of the Registry will be identified through a database search and entered into the Registry database. A review of the patient’s EMR will be conducted on an annual basis by the Investigator or designee to determine possible recurrence. If no follow-up data is available, the patient will be contacted by the Investigator or designee to seek information on recurrence only.
A waiver from the IRB of record will be requested for the requirement of obtaining written informed consent for both prospective and retrospective patients since no patient risk is involved and for which only recurrence rates and data associated with recurrence will be tracked.
Female patients eighteen or older.
New patients presenting to BMDA with a breast cancer diagnosis with planned radiation therapy and patients with who were treated beginning in October 2015 through initiation of this study.
Breast cancer patients only treated with non-radiological treatment.
Patients expected to receive treatment or follow-up care outside of BMDA.
Pregnant and/or breast feeding females
Secondary Trial ID Number